Toll Free: 1-888-928-9744

Cryptococcosis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 23 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cryptococcosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cryptococcosis - Pipeline Review, H1 2015’, provides an overview of the Cryptococcosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cryptococcosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cryptococcosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cryptococcosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cryptococcosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cryptococcosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cryptococcosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cryptococcosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cryptococcosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Cryptococcosis Overview 5
Therapeutics Development 6
Pipeline Products for Cryptococcosis - Overview 6
Pipeline Products for Cryptococcosis - Comparative Analysis 7
Cryptococcosis - Therapeutics under Investigation by Universities/Institutes 8
Cryptococcosis - Pipeline Products Glance 9
Early Stage Products 9
Cryptococcosis - Products under Investigation by Universities/Institutes 10
Cryptococcosis - Therapeutics Assessment 11
Assessment by Monotherapy Products 11
Assessment by Target 12
Assessment by Mechanism of Action 13
Assessment by Molecule Type 14
Drug Profiles 15
fluorcombstatin - Drug Profile 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecule for Candidiasis and Cryptococcosis - Drug Profile 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecule for Cryptococcosis and Candidiasis - Drug Profile 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule for Fungal Infections - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecule for Infectious Diseases - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecules for Cryptococcosis - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Cryptococcosis - Dormant Projects 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 22
Disclaimer 23
List of Tables

Number of Products under Development for Cryptococcosis, H1 2015 6
Number of Products under Development for Cryptococcosis - Comparative Analysis, H1 2015 7
Number of Products under Investigation by Universities/Institutes, H1 2015 8
Comparative Analysis by Early Stage Development, H1 2015 9
Products under Investigation by Universities/Institutes, H1 2015 10
Assessment by Monotherapy Products, H1 2015 11
Number of Products by Stage and Target, H1 2015 12
Number of Products by Stage and Mechanism of Action, H1 2015 13
Number of Products by Stage and Molecule Type, H1 2015 14
Cryptococcosis - Dormant Projects, H1 2015 21 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify